Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: Safety of avastin in lung trial (MO19390)

Journal of Thoracic Oncology

Volumn 7, Issue 1, 2012, Pages 203-211

  Laskin, Janessa ^a   Crinò, Lucio ^b   Felip, Enriqueta ^c   Franke, Fabio ^d   Gorbunova, Vera ^e   Groen, Harry ^f   Jiang, Guo Liang ^g   Reck, Martin ^h   Schneider, Claus Peter ⁱ  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Hospital de Caridade   (Brazil)

^e Cancer Research Center   (Russian Federation)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^h Hospital Grosshandorf   (Germany)

ⁱ Central Clinic Bad Berka   (Germany)

Author keywords

Bevacizumab; Elderly; Non small cell lung cancer (NSCLC); Safety; Vascular endothelial growth factor

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OPIATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM BLEEDING; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; GROUPS BY AGE; HEMOPTYSIS; HUMAN; HYPERTENSION; LARGE CELL CARCINOMA; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG HEMORRHAGE; LUNG METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONSQUAMOUS NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEINURIA; RECURRENT CANCER; TUMOR LOCALIZATION; VENOUS THROMBOEMBOLISM; WOUND COMPLICATION;

EID: 84555206070     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182370e02     Document Type: Article

References (33)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N EnglJ Med 2002;346:92-98. (Pubitemid 34438899)
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in nonsmall cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 2005;311:899-909.
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353 (Pubitemid 41095099)
4. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 (Suppl 2):ii39 -ii40.
5. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A southwest oncology group trial. J Clin Oncol 2001;19:3210-3218. (Pubitemid 32591438)
6. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002;20:4285-4291. (Pubitemid 35266288)
7. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024. (Pubitemid 46606280)
8. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997;33:2313-2314. (Pubitemid 28129168)
9. Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from surveillance, epidemiology and end results-medicare. J Clin Oncol 2004;22:4971-4978. (Pubitemid 46638623)
10. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007;25:5570-5577.
11. Townsley C, Pond GR, Peloza B, et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 2005;23: 3802-3810.
12. Gridelli C. The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Oncologist 2001;6 (Suppl 1):4-7. (Pubitemid 32155180)
13. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372. (Pubitemid 36395256)
14. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380-8388.
15. Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190-196. (Pubitemid 41702638)
16. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181. (Pubitemid 34162751)
17. Belani CP, Fossella F. Elderly subgroup analysis of a randomised phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005;104:2766-2774. (Pubitemid 41798287)
18. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003;98:779-788. (Pubitemid 36959275)
19. Quoix EA, Oster J, Westeel V, et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2010;28:2a.
20. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
21. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27:1227-1234.
22. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin/ gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-1809.
23. Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): A phase 4 study. Lancet Oncol 2010;11: 733-740.
24. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. 10. J Clin Oncol 2007;25:1553-1561. (Pubitemid 46733082)
25. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology Version 2.2011: Senior Adult Oncology. Available at: http://www.nccn.org. Accessed May 23, 2011.
26. Leighl N, Zatloukal P, Mezger J, et al. Efficacy and safety of bevacizumab- based therapy in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in the phase III BO17704 study (AVAiL). J Thorac Oncol 2010;5:1970-1976.
27. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003;97 (12 Suppl): 3133-3175.
28. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-1246. (Pubitemid 30321574)
29. Kumar A, Soares HP, Balducci L, et al. Treatment tolerance and efficacy in geriatric oncology: A systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol 2007;25:1272-1276. (Pubitemid 46646519)
30. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067. (Pubitemid 30035956)
31. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21: 1383-1389. (Pubitemid 46606420)
32. Balducci L. Geriatric oncology: Challenges for the new century. Eur J Cancer 2000;36:1741-1745.
33. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.